5th Annual Recombinant Antibodies (2012) Pp

1,514
-1

Published on

Email piyush.patel@visiongain.com for early bird discount

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,514
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
9
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

5th Annual Recombinant Antibodies (2012) Pp

  1. 1. 5th Annual Recombinant AntibodiesAdvances in bispecific, next-generation and monoclonal antibody development and translation 17th – 19th January, 2012, Visiongain Conference Centre, London, UK BOOK NOW! Key Speakers Paulo Fontoura, Global Head CNS Translational Medicine, F. Hoffmann-La Roche Jennifer Sims, Global Head of Biologics Safety & Disposition, Novartis Ulrich Brinkmann, Scientific Director, Biologics Engineering, Roche Pharma Research and Early Development Matthew Sleeman, Director of Biology, MedImmune Lolke de Haan, Director of Toxicology, Biologics Safety Assessment, MedImmune Andrew Nesbitt, Associate Director, Cimzia Mechanism of Action Group, UCB Celltech Jürgen Michael Schanzer, Research Scientist Biologics Engineering, Roche Diagnostics Maria A.T. Groves, Senior Scientist, Lead Generation, ADPE, MedImmune John McCafferty, Director of Research, University of Cambridge Kerry Chester, Professor Molecular Medicine, University College London Christian Rohlff, Chief Executive Officer, Oxford BioTherapeutics Matthew Baker, Chief Scientific Officer, Antitope Nicolas Fischer, Head of Research, NovImmune Lihui Xu, Group Leader, Antibody Technology and Generation, Merrimack Pharmaceuticals Pre-conference Workshop, Tuesday 17th January, 2012 Antibody drug conjugates– finally delivering their payload Led by: Shane Olwill, Senior Director R&D, Pharmacology, Pieris Organised By Driving the Industry Forward | www.futurepharmaus.comMedia Partners To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/rabs
  2. 2. Conference Introduction 5th Annual Recombinant Antibodies 17th - 19th January 2012, London, UK Dear Colleague, Media Partners: rom Kohler and Millstein’s pioneering efforts to today’s multifactorial approach, F PharmiWeb.com is the leading industry-sponsored portal for monoclonal antibodies have consistently improved the clinical outcome of disease the pharmaceutical sector. Supported by most of the leading progression. As shown by Avastin and Lucentis, antibodies have blockbuster potential, now pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, number eight of today’s 20 top-selling biotech drugs. With ongoing growth rates nearing events listings and international jobs to industry professionals across Europe and the US. 15%, the global market will reach $80 by 20251 as new approvals and a growing world For further information please email: corporate@pharmiweb.com population drive patient demand. BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY ith over 25 products approved for human use and 26 candidates in Phase III trials, W WORLD. It is based and located in Warsaw, Poland. mAbs remain arguably the most exciting proteins today. Pharmaceutical companies have Biotechnology World was founded in 2007 to provide the become more interested, especially in fully-human, bi-specific and scFv proteins, as these world’s biotech and pharma information and market to make it universally accessible progress through development for new indications including ophthalmic, autoimmune and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread and viral diseases. of information in different channels. BIOTECHNOLOGY EUROPE offers companies ith competition intensifying, rational design to target multiple disease pathways has W completed internet public relations, publication and marketing solutions. One of the become ever more important in an increasingly crowded market. This includes utilising mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma informatics, omics, and systems biology insights. Decreasing immunogenicity, improving Sector in Europe to global biotechnology, pharmaceutical and life science activities. receptor-ligand interactions and decreasing in vivo clearance rates remain ongoing For further information please visit: www.biotechnology-europe.com challenges, as do more effective biodistribution, targeting, tissue penetration and uptake. Future Pharmaceuticals has forged powerful relationships with Driving the Industry Forward | www.futurepharmaus.com Addressing these needs, Visiongain’s Fifth Annual Recombinant key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means Antibodies conference showcases how such goals are being met to procure and plan implementation strategies based on the topics covered. Positioned by leading experts. Whether your interests lie in basic, pre-clinical, to be an authoritative resource within top pharma companies as well as small, translational or clinical research, business diversification, licensing or specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep partnering, attending this conference will empower you to: penetration into a highly targeted and responsive audience, bridging the gap between • etwork with key decision makers at leading companies including Roche, Novartis and N the industries’ top issues and the solutions top-tier vendors can provide. MedImmune For further information please visit: www.futurepharmaus.com • Improve the potency of IgG molecules for ADCC, ADCP and CDC applications InPharm is the online platform for exclusive pharmaceutical • Enhance immune effector functions through targeted Fc region engineering news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. • Increase in vivo circulation time with conjugated immunoglobulins • Extend pharmacokinetic half-life and exposure For further information please visit: www.inpharm.com • Better utilise, deploy and evaluate in silico tools during early-phase research • Optimise antigen-binding domains • Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity • Assess new technologies for selecting antibody attributes Poster Presentation • Maximise site-specific drug loading for bispecific antibodies At a busy conference it is hard to make sure everyone who shares your interests knows • btain new data on inflammatory disease, and solid and liquid cancer targets O what you are doing. Maximise your time at Visiongain’s 5th Annual Recombinant • lock activation of angiogenic signalling pathways and disrupt the tumour B Antibodies meeting by sharing your results in a poster presentation. With a plethora of key microenvironment decision makers, take advantage of this senior networking opportunity. I look forward to meeting you at the conference Please send your 200 word abstract, in English, to: info@visiongainglobal.com for Best regards approval. The deadline for submissions is Tuesday, 10th January, 2012. Please include contact details for the corresponding author(s). Academic institutions will not be charged a fee if booked as full-price delegates. Posters submitted by pharmaceutical and biotechnology firms will be charged a fee of £199. Posters submitted by service providers / vendors are welcome and will be subject to Nicholas Stone evaluation. Upon approval a fee of £500 will apply. Two delegates from your organisation Head of Conferences must be booked at full price to present a poster. Please note that all posters will be displayed at the discretion of Visiongain Ltd and are subject to approval. Due to limited space, please register your interest early. Who should attend? Presidents, Chief Executive Officers, Chief Scientific Officers, Vice Presidents, Professors, Heads, Directors, Principal/Senior Scientists and Managers/Team Leaders of: • Antibody design, production and development Sponsorship and exhibition opportunities • Recombinant DNA/molecular biotechnology This event offers a unique opportunity to meet and do business with some of the key • Protein/biochemical engineering • Biotherapeutics players in the pharmaceutical and biotech industries. If you have a service or product • Assay and cell display technologies to promote, you can do so at this event by: • Bio-analytical and protein-analytical R&D, and analytical chemistry • Process development • Hosting a networking drinks reception • Preclinical/clinical research and development • Oncology • Taking an exhibition space at the conference • CNS, autoimmune and inflammatory disease research • Advertising in the delegate documentation pack • Arthritis, colorectal/breast/lymphoma/prostate/lung cancer R&D • Immunobiology and immunogenicity testing • Providing branded bags, pens, gifts, etc. • Pharmacovigilance If you would like more information on the range of sponsorship or exhibition possibilities • Business and alliance development • Marketing and licensing for visiongains 5th Annual Recombinant Antibodies Conference, please contact us: • Biosimilars • Contract manufacturing and research organisations Damian Gorman, +44 (0)20 7549 9934 • Regulatory affairs, pharmaceutical and patent law • Pharmaceutical and patent law damian.gorman@visiongainglobal.comVisiongain, (2010). Therapeutic Monoclonal Antibodies: World Market 2010-20251
  3. 3. Pre-Conference Interactive Workshop 5th Annual Recombinant Antibodies Tuesday 17th January 2012 Antibody drug conjugates– finally delivering their payloadLed by: Shane Olwill Timings: 9:30 - 10:00 Coffee & Registration 0 Senior Director R&D, Pharmacology 10:00 - 15:00 Workshop Pieris T iming includes lunch and refreshment breaksAgenda: About your workshop leader:The development of antibody drug conjugates (ADCs) has faced Dr Shane Olwillconsiderable hurdles over the past decade with research effortshampered by target selection, optimal antibody format, conjugation Dr Shane Olwill has spent over a decade in oncology-focused drugchemistries, bioprocessing and choice of drug payloads. However, a new discovery, with a specific interest in the development of novel biologics.wave of optimism has emerged following successful clinical trial data At Pieris, Shane is responsible for managing preclinical oncologyfrom lead compounds such as TDM-1 (ImmunoGen – Roche/Genentech)in breast cancer and SGN35 (Seattle Genetics-Millennium/Takeda) being programs from discovery into the clinic. He is also responsible forevaluated for the treatment of Hodgkin’s lymphoma. This has led to a characterizing ADC applications of anticalins. Prior to joining Pieris,heightened level of interest in the area. Shane was Director of Research at Fusion Antibodies Ltd. Shane receivedThis workshop will provide an introduction to the development of ADCs his B.Sc. in Biomedical Sciences and Ph.D. in Molecular Haematology/including key selection criteria for ADC components. It will review thecurrent status of ADCs in development, discussing how they can aid the Oncology from the University of Ulster.delivery of potent anti-neoplastic molecules with reduced toxicity andimprove the therapeutic index when compared to naked antibodies. The About: Pieris. The Anticalin Company™workshop will also introduce how next generation non-IgG scaffolds suchas Anticalins may further enhance their therapeutic index. Pieris AG is an independent clinical stage biotechnology company that is dedicated to the discovery and development of life changing drugs. Our proprietary technology, the Anticalin® technology, encompasses a novelAbout visiongain:Visiongain is a specialist business information company focused on class of therapeutic proteins that addresses a broad range of therapeuticproviding cutting edge products and services across the Pharmaceutical/ applications and targets. Pieris has a growing, exciting and differentiatedBiotech, Telecommunications, Defence and Finance sectors, whichinclude reports, conferences, online daily news and offline news drug pipeline across multiple disease areas. Pieris will commercializeanalysis and bespoke consultancy. With a commitment to innovation Anticalin therapeutics through strategic partnerships, involving bothand excellence, visiongain offers flexible solutions to meet our clients’business intelligence needs, providing the right information at the its proprietary pipeline and its de novo drug discovery capabilities. Theright time to facilitate the commercial decision-making process. Our company has four ongoing discovery and development collaborations:pharmaceutical products include Pharma Business Daily, the leadingdaily email newsletter for the pharmaceutical, biotech and healthcare Daiichi Sankyo, Takeda San Francisco, Allergan, Sanofi-Aventis and Sanofi-industries, and a range of independent, high-quality, in-depth reports Pasteur. Pieris is well financed, having closed Series A and B roundscovering focused and topical areas of concern. Our pharmaceuticalconferences address the hottest commercial, regulatory and technical of venture-backed financing, led by Global Life Science Ventures andtopics and provide an ideal forum for debate and networking for OrbiMed Advisors.pharmaceutical professionals from around the world.For further information, please visit: www.visiongain.com For further information, please visit: www.pieris-ag.com
  4. 4. Day 1 5th Annual Recombinant Antibodies Wednesday 18th January 2012 09:00 Registration and refreshments 12:40 Networking lunch 09:30 Opening address from the Chairs 13:40 Bispecific antibodies for targeted payload delivery Kerry Chester • Generation & optimisation of hapten-binding bispecific antibodies Professor Molecular Medicine • Complexation and targeted delivery of haptenylated payloads University College London • Targeted payload delivery in vitro and in vivo Matthew Sleeman Director of Biology Ulrich Brinkmann MedImmune Scientific Director, Biologics Engineering Roche Pharma Research and Early Development 09:40 Biology of Fc receptors: impact on therapeutic antibodies 14:20 Rational engineering of antibody therapeutics • Functional importance of FcγRs targeting multiple oncogene pathways • D20 therapeutic antibodies depend on immune cell Fc C • olecular format and pharmaceutical properties in bispecific M receptor interactions antibody design • Tumour burden determines the effector mechanism of CD20 antibodies • Identifying best targets and optimal design characteristics • Engineering a bispecific antibody through a therapeutic design cycle Jeanette Leusen Associate Professor Lihui Xu University Medical Centre Utrecht Group Leader, Antibody Technology and Generation Merrimack Pharmaceuticals 10:20 Antibody engineering by design • PK and receptor occupancy models to future-proof antibody design 15:00 Afternoon refreshments • Harnessing the power of phage display to meet specific design criteria • ombining biology, pharmacology and PD to translate preclinical C 15:20 PASylation: a superior approach to engineer observations into the clinic antibody fragments with extended plasma half-life • Phase I clinical results and their relation to the theoretical model • c fusion, HSA fusion and PEGylation strategies to achieve F Matthew Sleeman prolonged circulation Director of Biology • ASylation (genetic fusion with a long disordered polypeptide comprising P MedImmune Pro, Ala and Ser residues) as an alternative • reclinical applications of PASylation for Fab fragments and other P 11:00 Morning refreshments biopharmaceuticals Arne Skerra 11:20 Development of tetravalent, bispecific CCR5 Managing Director antibodies with antiviral activity against CCR5 XL-protein monoclonal antibody-resistant HIV-1 strains • Construction of a novel tetravalent, bispecific antibody to block HIV entry • esign optimisation of scFvs including disulfide and increased linker D 16:00 Monoclonal and next-generation antibodies- where length stabilization are we and what are the prospects for the future? PANEL DISCUSSION • nhanced antiviral potency against wildtype and CCR5-antibody E Topics discussed will include improving antibody efficacy from initial target resistant HIV-1 strains binding, and dual blockade of disease mediators with bispecific antibodies. Jürgen Michael Schanzer The future of conjugated therapies, engineering enhanced PK/PD and the Research Scientist Biologics Engineering impact of systems biology on clinical development will also be discussed. Roche Diagnostics Join this lively session and email your questions for the panel to: nicholas.stone@visiongainglobal.com 12:00 κ λ-body: a manufacturing friendly bispecific antibody format • n contrast to other bispecific formats, κλ -Bodies are unmodified I 16:40 Closing remarks from the Chair fully human IgGs • λ-Bodies rely on the assembly of a kappa and a lambda light κ chain with a common heavy chain • Development of a streamlined platform for producingκλ-bodies 16:50 Networking drinks Nicolas Fischer Take your discussions further and build new Head of Research NovImmune relationships in a relaxed and informal setting Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
  5. 5. Day 2 5th Annual Recombinant Antibodies Thursday 19th January 201209:00 Registration and refreshments 12:40 Networking lunch09:30 Opening address from the Chair 13:40 Presentation to be announced Paulo Fontoura Andrew Nesbitt Global Head CNS Translational Medicine Associate Director, Cimzia Mechanism of Action Group F. Hoffmann-La Roche UCB Celltech09:40 Beyond natural antibodies: the power of in vitro 14:20 Monoclonal antibody therapy in multiple sclerosis: display technologies paradigm shifts and emerging challenges • Unique features of display technologies • mAbs may offer considerable advantages over other therapies for MS • Recognition of modifications in proteins, and cell surface receptors • However, efficacy comes with significant clinical risks • Exploiting the recombinant nature of in vitro selected mAbs John McCafferty • btaining the best benefit-risk ratio, monitoring and preventing emergent O Director of Research safety concerns University of Cambridge 15:00 Afternoon refreshments10:20 Generation of differentiated biological therapeutics 15:20 Generation of therapeutic antibodies against • A review of biologics discovery at MedImmune inflammatory disease and cancer targets, with a low CASE STUDY • Project case study examples will be given risk of clinical immunogenicity • Examples of differentiated products will be included Matthew Baker Maria Groves Chief Scientific Officer Senior Scientist, Lead Generation, ADPE Antitope MedImmune 16:00 Conjugated mAbs for cancer treatment11:00 Morning refreshments • Improved cytotoxic treatments • Anti-tumour activity through target cell activation 11:20 On setting the first dose in man: quantitating • Evidence from in vivo trials biotherapeutic drug-target binding through Christian Rohlff pharmacokinetic and pharmacodynamic models Chief Executive Officer • Contributions of in vitro and in vivo studies Oxford BioTherapeutics • Roles and limitations of in vivo animal models • Overcoming challenges for clinical pharmacology 16:40 Chair’s closing remarks Jennifer Sims Global Head of Biologics Safety Disposition Novartis 16:50 End of conference12:00 Modulation of Fc receptor function: from principle to translation in the clinic • c engineering resulting in decreased or increased effector function, F or half life extension CASE STUDY • Utility of translational PK/PD to predict human safety and efficacy • Three examples illustrating issues arising during drug development Lolke de Haan Director of Toxicology, Biologics Safety Assessment MedImmune
  6. 6. Registration Form 5th Annual Recombinant Antibodies 17th - 19th January 2012, London, UK Angel Conf. code PP Pentonville Road 5th Annual Recombinant CiStandard Prices ty Antibodies Ro adConference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80Conference only Fee: £1299 VAT: £259.80 Total: £1558.80 17th - 19th January 2012 Old StreetWorkshop only Fee: £599 VAT: £119.80 Total: £718.80 Location: Visiongain Conference Centre Old Street Address: Number of bookings: Total cost: 230 City Road City Road London EC1V 2TTPromotional Literature Distribution UKDistribution of your company’s promotional literature to all conference attendees Fee: £999 VAT: £199.80 Total: £1198.80 How to bookDetails Email: piyush.patel@visiongain.com Web: http://www.visiongain.com/rabs Forename: Surname: UK Office: Tel: +44(0) 20 7549 9961 Job Title: Company: Fax: +44(0) 20 7549 9932 Visiongain LtdMain Switchboard Number: BSG House 230 City Road LondonAddress: EC1V 2QY UK General information Venue: Venue: Directions: Visiongain Conference Centre 230 City Road, London, EC1V 2TT. United Country: Postcode: Kingdom. Closest tube station is Old Street (Northern Line). Accommodation: Thistle City Barbican, Central Street, Clerkenwell, London, EC1V 8DS, Phone: 0871 376 Phone: Fax: 9004 / +44 845 305 8304, Fax: 0871 376 9104 / +44 845 305 8343 http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.htmlEmail: Travelodge London City Road Hotel, 7-12 City Road, London, EC1Y 1AE, Tel: 0871 984 6333, Fax: 0207 628 2503, http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340 Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain Signature: Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee may be requested if payment has not been received in full before the event. Visiongain Ltd reserves the I confirm that I have read and agree to the terms and conditions of booking right to charge interest on unpaid invoices. Substitutions/name changes or cancellations: There is a 50% liability on all bookings once Methods of payment made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or after one month before the start of the event. Should you decide to cancel after this date, the full invoice Payment must be made in sterling must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places By Mail: Complete and return your signed registration form together with your cheque payable between conferences. However, if you cannot attend the conference, you may make a substitution/name change at any time, as long as we are informed in writing by email, fax or post. Name changes and to Visiongain Ltd and send to: visiongain Ltd, BSG House, 226-236 City Road, London, EC1V 2QY, UK substitutions must be from the same company or organisation and are not transferable between By Fax: Complete and fax your signed registration form with your credit card details countries. Please note that discounted delegates places at a visiongain event are non refundable.to +44 (0) 20 7549 9932 Invoice alterations: There will be an administration charge of £50 for any changes to an invoice, excluding substitutions/name changes, requested by the customer. This will be charged to the By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details customer by credit card prior to the changes being made. Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive By Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932 briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled By Bank Transfer: due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or Visiongain Ltd A/C: visiongain Ltd expenses, which may be incurred by the customer as a consequence of the event being postponed or Barclays Bank Sort Code: 20-71-64 cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the cost of the registration, travel and expenses.Piccadilly Branch Account No: 6038 7118 Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data 48 Regent Street Swift Code: BARC GB22 Protection Act 1988. Your personal information contained in this form may be used to update you on London, W1B 5RA IBAN: GB80 BARC 20716460387118 visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may also share your data with external companies offering complementary products or services. If you Please debit my credit card: wish for your details to be amended, suppressed or not passed on to any external third party, please send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London, Access MasterCard Visa American Express EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details. Please allow approximately 30 days for your removal or update request to be applied to our database. Following your removal or update request, you may receive additional pieces of communication from Card number: visiongain Ltd during the transitional period, whilst the changes are coming into effect. Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly Expiry Date: recommend you obtain). VAT: VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT Security number (last 3 digits on back of credit card): incurred by contacting Eurocash Corporation plc +44 (0) 1273 325000, eurocash@eurocashvat.com. Eurocash specialise in recovering cross-border VAT.Signature: How we will contact you: Visiongain Ltd’s preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.Cardholder’s name: Unable to attend Obviously nothing compares to being there but you need not miss out. Simply tick the box and send News updates with your payment. You will receive speaker talks in PDFs two weeks after the event.Please tick if you do not want to receive email news updates in the future Yes, please send me speaker talks Price£550 VAT:£110 Total:£660 www.visiongain.com/rabs

×